Meanwhile, the approval of Onpatro (Patisiran), the first small interfering RNA (siRNA)-based drug for the treatment of nerve damage caused by hereditary transthyretin-mediated amyloidosis, raises the prospect of miRNA as a therapeutic agent for genetic diseases. This evidence concerns the gene TTR and hereditary disease.